Zhejiang, China

Lin Qian

This inventor holds 1 USPTO granted patent. Top assignee: Zhejiang Hisun Pharmaceutical Co., Ltd.. Active years: 2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lin Qian. Retrieved from https://idiyas.com/inventor/lin-qian-avughlv5

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2021

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Lin Qian: Innovator in Pharmaceutical Chemistry

Introduction: Lin Qian is a notable inventor based in Zhejiang, China. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of therapeutic agents. His work focuses on innovative compounds that have the potential to impact medical treatments.

Latest Patents: Lin Qian holds a patent for a cyano-substituted heteroarylpyrimidinone derivative. This invention includes a preparation method and its use as a therapeutic agent, specifically as an acetyl-CoA carboxylase (ACC) inhibitor. The patent outlines the structure of the compound and the definition of each substituent, providing a comprehensive understanding of its application in medicine.

Career Highlights: Lin Qian is associated with Zhejiang Hisun Pharmaceutical Co., Ltd., where he has been instrumental in advancing research and development efforts. His expertise in pharmaceutical chemistry has led to innovative solutions that address various health challenges.

Collaborations: Lin Qian has worked alongside talented colleagues, including Hejun Lv and Dongliang Guan. Their collaborative efforts have contributed to the success of projects within the pharmaceutical sector.

Conclusion: Lin Qian's contributions to pharmaceutical chemistry and his innovative patent demonstrate his commitment to advancing medical science. His work continues to inspire future developments in therapeutic agents.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…